Mutations in Presenilin-1 (PS1) are linked to early onset of familial Alzheimer's disease (FAD) and lead to increased production of Abeta42, a peptide that is accumulated during aging and plays a critical role in AD pathogenesis. PS1 is a multi- pass transmembrane protein that is essential for mouse embryonic development and is required for Abeta peptide generation. PS1 also interacts with beta-catenin and has been implicated in regulating beta-catenin stability in vitro. The in vivo function of PS1 in the adult central nervous system and other tissues is poorly understood, due to the early lethal phenotype of the PS1 null mouse. We have reported that transgenic mouse lines expressing either the wild-type human PS1 protein or PS1 containing the A246E FAD mutation, under the neuronal-specific human Thy-1 promoter, can protect the PS1 null mouse against embryonic lethality and simultaneously restore Abeta expression. This "rescue" system allows us to further define PS1 in vivo activities by introducing specific modifications, such as PS1 mutations affecting Abeta synthesis or beta-catenin interaction respectively. It also offers us a unique opportunity to study the effect of PS1 loss-of-function in adult peripheral tissues of existing mice as they are rescued by a neuronal specific expression of the PS1 transgene. Our preliminary data indicate that lack of PS1 expression in the skin of these mice leads to epidermal hyperplasia and neoplasm, suggesting that PS1 may play an important role in skin tissue, possibly through beta-catenin signaling pathway. Our long-term objective is to use our established rescue system to dissect multiple pathways which PS1 seems to participate in vivo. The specific aims of the proposal are: 1] To explore the molecular mechanism of PS1 activity in adult epidermis; 2] To identify the in vivo significance of PS1- beta-catenin interaction; 3] To determine whether the developmental activity and Abeta generating property of PS1 can be differentiated. We believe that these studies will advance our understanding of the physiological function of PS1 and the pathogenic mechanism of Alzheimer's disease.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Mus musculusagingamyloid proteinsbiological signal transductioncadherinscentral nervous systemdevelopmental neurobiologyembryo /fetus tissue /cell culturegene deletion mutationgene expressiongene targetinggenetically modified animalsimmunocytochemistryin situ hybridizationlaboratory mousemembrane transport proteinsmutantnorthern blottingsphenotypepresenilinprotein biosynthesisprotein protein interactionprotein structure functionskinwestern blottings
National Institute of Neurological Disorders and Stroke
CFDA Code
854
DUNS Number
051113330
UEI
FXKMA43NTV21
Project Start Date
20-April-2000
Project End Date
31-March-2004
Budget Start Date
01-April-2002
Budget End Date
31-March-2003
Project Funding Information for 2002
Total Funding
$299,000
Direct Costs
$200,000
Indirect Costs
$99,000
Year
Funding IC
FY Total Cost by IC
2002
National Institute of Neurological Disorders and Stroke
$299,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01NS040039-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01NS040039-03
Patents
No Patents information available for 5R01NS040039-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01NS040039-03
Clinical Studies
No Clinical Studies information available for 5R01NS040039-03
News and More
Related News Releases
No news release information available for 5R01NS040039-03
History
No Historical information available for 5R01NS040039-03
Similar Projects
No Similar Projects information available for 5R01NS040039-03